Abstract The Database of Individuals at High Risk for Breast, Ovarian, or Other Hereditary Cancers at the Arizona Cancer Center in Tucson, Arizona assesses cancer risk factors and outcomes in patients with a family history of cancer or a known genetic mutation. We analyzed the subset of clinic probands who carry deleterious BRCA gene mutations to identify factors that could explain why mutations in BRCA2 outnumber those in BRCA1. Medical, family, social, ethnic and genetic mutation histories were collected from consenting patients' electronic medical records. Differences between BRCA1 and BRCA2 probands from this database were analyzed for statistical significance and compared to published analyses. A significantly higher proportion of our clinic probands carry mutations in BRCA2 than BRCA1, compared with previous reports of mutation prevalence. This also holds true for the Hispanic sub-group. Probands with BRCA2 mutations were significantly more likely than their BRCA1 counterparts to present to the high risk clinic without a diagnosis of cancer. Other differences between the groups were not significant. Six previously unreported BRCA2 mutations appear in our clinic population. The increased proportion of probands carrying deleterious BRCA2 mutations is likely multifactorial, but may reflect aspects of Southern Arizona's unique ethnic heritage.
Introduction
BRCA1 and BRCA2 mutations have been found in women from a broad range of racial and ethnic backgrounds [1, 2] . These genetic mutations are inherited in an autosomal dominant fashion and significantly increase risk of both breast and epithelial ovarian cancer. Women with a BRCA1 mutation have a lifetime probability of developing breast cancer of 65-81 % and epithelial ovarian cancer of up to 35-60 %, while women carrying a BRCA2 mutation have a 45-85 % chance of developing breast cancer and a 10-27 % chance of developing epithelial ovarian cancer [3] . BRCA mutations also predispose to melanoma, prostate and pancreatic cancers [4] . While BRCA1 and BRCA2 mutations are responsible for a minority of breast and ovarian cancers, they are found in as many as 5-10 % of patients with breast and epithelial ovarian cancers [5, 6] . Chemoprevention and prophylactic surgery (bilateral mastectomy and bilateral salpingo-oophorectomy) can decrease cancer risk in carriers of BRCA1 and BRCA2 mutations [7] [8] [9] [10] [11] [12] . These mutations continue to be a focus of intense investigation for development of better prevention strategies and treatment modalities.
In studies reporting other high risk clinic databases, BRCA1 mutations are uniformly more frequent than BRCA2 mutations [1, 2, 13, 14] . The largest published analysis of genetic test results of commercially-tested patients found that among 46,276 patients tested, 5,795 harbored a deleterious BRCA gene mutation [2] . Of these, 7.2 % carried a deleterious BRCA1 mutation and 5.3 % of patients carried a deleterious BRCA2 mutation. Thus 42 % of mutations were in BRCA2, while 58 % affected BRCA1. We analyzed the Hispanic patients reported by Hall [2] and found that 36 % (from a total of 290 patients) carried a deleterious BRCA2 mutation.
The University of Arizona Cancer Center (UACC) established a high risk clinic in 2004 and it has grown steadily since. As of January 2012, 251 patients were enrolled in a database to collect information about the clinical course of high risk patients. Unexpectedly, we observed that BRCA2 mutations are more common than BRCA1 mutations in our clinic population. This is, to our knowledge, a unique finding. We considered three hypotheses to explain this phenomenon: (1) a previously unrecognized mutation may be present in this population; (2) the unique ethnic composition of our community might have allowed maintenance of unique allele frequencies; or (3) by virtue of being a high risk clinic, we attract patients by marketing aimed at providers and/or the community and might have captured a unique population of patients who differ from those previously reported from high risk clinics. To address the first two hypotheses, we asked whether the BRCA1/BRCA2 ratio is skewed in probands who selfidentify as Hispanic or Ashkenazi Jewish. We also asked whether any specific mutations are over-represented in our probands. Some data suggest that BRCA2 carriers develop cancer at an older age than their BRCA1 counterparts [15, 16] . Thus, we analyzed the age at which probands presented to initiate preventative care, their prior cancer diagnoses and the burden of cancer in their pedigrees to address the third hypothesis.
Methods
The Database of Individuals at High Risk for Breast, Ovarian, or Other Hereditary Cancers [BIO # A06-028 (06-0477-04)] at the UACC in Tucson, AZ is a collection of data from consented patients with known genetic predisposition to cancers or a significant personal and/or family history for cancers that suggests an inherited cancer predisposition. Between January 2006 and January 31, 2012, 251 patients were consented. Data regarding the medical, family, social, and genetic mutation history from this cohort were collected from the patients' electronic medical records. For the purposes of this study, we analyzed patients who have known BRCA1 or BRCA2 mutations, excluded patients carrying mutations classified as variants of uncertain significance, and included only the proband from each family. We re-analyzed pedigrees from individuals with the same mutation to exclude relatedness and were left with 52 probands. Information about specific BRCA mutations, personal and family cancer history, ages at presentation and diagnosis, whether the proband had been diagnosed with cancer when she presented to the clinic, and self-reported ethnic background were collected from a chart review for further analysis.
A binomial exact test was used to compare the proportion of BRCA1:BRCA2 mutations in different populations. Frequencies of BRCA1 to BRCA2 mutations in subgroups of probands with shared ethnicity, a previous diagnosis of cancer, or varying numbers of relatives with cancer were compared using the Fisher Exact test or a Chi squared test, when appropriate. Finally, the t test was employed to compare ages at presentation to the clinic between BRCA1 and BRCA2 carriers. All analyses were performed using the SAS and Minitab 15 programs.
Results
Analysis of the mutations carried by probands in our highrisk clinic database revealed that 21 women carry mutations in BRCA1, while 31 carry BRCA2 mutations (Table 1) , which differs significantly from previous reports (p = 0.01; [1] ).
We analyzed the self-reported ethnic background of mutation carriers. In the 2010 U.S. Census, 34.6 % of Pima County, AZ residents reported being of ''Hispanic or Latino origin'' compared to 29.6 % of all Arizonans and 16.3 % of all Americans [17] . In our registry, 15 probands report Mexican or Hispanic ancestry (28.8 %). Five of these women carry BRCA1 mutations, while 10 carry BRCA2 mutations, which differs significantly from previous reports (p = 0.01; Table 1 ; [2] ). In Pima County, AZ 2.4 % of residents report Ashkenazi Jewish ancestry [18], compared with 11 % of clinic probands. Despite underrepresentation of one group and over-representation of the other, there is no significant difference between the representations of Ashkenazi Jewish or Hispanic ancestry between BRCA1 and BRCA2 carriers.
Analysis of specific deleterious mutations reveals several points: (1) all three of the Ashkenazi Jewish founder mutations are present (BRCA1 187delAG, BRCA1 5385insC, and BRCA2 6174delT); (2) the BRCA2 886del-GT mutation is found in four probands, who are believed to be unrelated based on careful comparison of known family relationships and pedigrees; (3) there are six deleterious BRCA2 mutations that have not been previously reported, one of which (8822insT) is found in two apparently unrelated probands.
The 886delGT mutation has been reported 37 times in the National Human Genome Research Institute database containing 14,780 BRCA2 mutations [19] . Finding this mutation in four apparently non-related probands is statistically significant (p \ 0.0001; binomial exact test). These four probands all self-identify as Hispanic and one has a personal history of cancer. Three of the four probands report having more than seven cancer-affected family members (range 8-10). All probands have family members affected by breast cancer; two have a family history of ovarian cancer. Family histories of pancreatic, testicular, stomach, and liver cancers as well as leukemia were also reported. The age of presentation to the high risk clinic varies from 26 to 49 years.
Among the seven probands who carry previously unidentified mutations, two report Mexican ancestry, two Native American ancestry, two Asian or Pacific Islander heritage, and one proband reports Caucasian ancestry. Three of the probands carrying previously unreported mutations have diagnoses of cancer: two have had breast cancer (diagnosed at ages 39 and 42 years) and one has ovarian cancer (diagnosed at age 64 years, found during her evaluation for prophylactic oophorectomy).
In order to evaluate our hypothesis that BRCA2 overrepresentation could be expected in high risk clinic recruiting from healthy community members, we asked whether probands presented to the clinic as a result of a cancer diagnosis or because of high risk status (known BRCA mutation or suspicious family history). BRCA1 carriers were significantly more likely to present as a result of cancer diagnosis, while BRCA2 carriers more often presented as a result of high risk status (Table 2 ; p = 0.04).
The difference in the proportion of probands with a new or previous cancer diagnosis at the time of presentation could be attributed to the previously reported difference in the age of cancer diagnosis between BRCA1 and BRCA2 mutation carriers [15, 16] . To explore this, we examined the ages at which probands presented to the high risk clinic and the age at which they were diagnosed with their first incidence of cancer (some probands have [1 cancer diagnosis). The average age of initial presentation to high risk clinic ranges from 27 to 69 years for BRCA1 probands and 19-69 years for BRCA2 probands. Neither age of first presentation nor age of first cancer diagnosis was significantly different between BRCA1 and BRCA2 mutation carriers.
We evaluated the total percentage of probands with cancer diagnoses (either before or after initial presentation to care) and found no statistically significant difference between BRCA1 and BRCA2 carriers. Sub-analysis of probands with either breast or epithelial ovarian/primary peritoneal cancers also revealed no significant difference in the percentage of probands with BRCA1 and BRCA2. One proband in the BRCA1 group and two in the BRCA2 group were diagnosed with both breast and epithelial ovarian/ primary peritoneal cancers. Two probands in the BRCA1 group had non-breast, non-epithelial ovarian cancer as did three probands in the BRCA2 group.
In order to further evaluate the hypothesis that BRCA2 carriers would present to clinic because of multiple affected relatives, we examined the pedigrees of each proband for the number of first-and second-degree relatives with cancer. We analyzed BRCA-associated cancers, cancers not traditionally associated with BRCA mutations, and the total number of relatives in the proband's pedigree with any type of cancer. Comparison of BRCA1 to BRCA2 carriers did not yield statistically significant differences in any of these analyses.
Discussion
Analysis of our database demonstrates that we have a significantly greater representation of deleterious BRCA2 BRCA mutation distribution 85 mutations than would be expected based on the published analysis of BRCA mutations [2] . Detailed, retrospective analysis of our patient records for identity of specific mutations, reported ethnicity, timing of presentation to care, timing of cancer diagnoses, and personal and family history of cancer reveals some patterns and even more questions. The higher proportion of BRCA2 carriers is likely due in part to finding the BRCA2 886delGT mutation in four probands, as well as six previously unreported BRCA2 mutations (8822insT, 2121delT, 4075delAG, 4363delC, 5103delAA, and 6873delC). All four of probands carrying BRCA2 886delGT and the one carrying 8822insT report Hispanic ancestry. Five other new mutations were found in women who did not report Hispanic ancestry. While our sample size is low, the excess of newly identified or rare mutations in people reporting Hispanic ancestry suggests that the mutation complement in our community differs from previously studied Hispanic communities [2, 20] . The haplotypes on which the 886delGT resides should be analyzed for common haplotypes suggestive of a founder effect [20] and interrelationships between families further probed.
We hypothesized that BRCA2 carriers are more likely than BRCA1 carriers to be referred to the ''high risk'' clinic because they are identified as being high risk prior to a diagnosis of cancer, based on a combination of later age at diagnosis of cancer and more complicated pedigrees. In order to test this hypothesis, we asked whether probands had a cancer diagnosis at time of presentation to care, and we compared the age of cancer diagnosis as well as the number of family members with cancer in BRCA1 and BRCA2 mutation carriers. There was no difference between the numbers of first, second, or total relatives with cancer between the two groups or in the age of cancer diagnosis between BRCA1 and BRCA2 carriers in our population. We did find, however, that BRCA2 probands were significantly more likely to present for cancer prevention efforts before a diagnosis of cancer. Thus, the later age of cancer diagnosis in BRCA2 carriers might provide a longer window of opportunity to establish a preventative care regimen; however the lack of a difference in age at subsequent cancer diagnosis remains confusing. Closer analysis suggests, also, that patients initially diagnosed with breast cancer remain with their oncologist, instead of transferring to the high-risk cancer prevention clinic. Thus, earlierdiagnosed patients, who might be enriched for BRCA1 mutations, may simply not be enrolling in our clinic. If this is true, then it is not clear how at-risk relatives are being identified, counseled or monitored?
Our database provides an opportunity to gain a better understanding of patients with BRCA mutations and of our clinic population. The factors leading to our excess of BRCA2 mutations are likely complex and may have biological, epidemiological, and financial roots. Exploring the unique aspects of our high-risk clinic has identified issues that might be preventing optimal care for all community members.
